Tumor targeting by an aptamer

…, YF Chang, CK Lynott, J Heil, S Borkowski… - Journal of Nuclear …, 2006 - Soc Nuclear Med
Aptamers are small oligonucleotides that are selected to bind tightly and specifically to a target
molecule. We sought to determine whether aptamers have potential for in vivo delivery of …

Application of locked nucleic acids to improve aptamer in vivo stability and targeting function

KS Schmidt, S Borkowski, J Kurreck… - Nucleic acids …, 2004 - academic.oup.com
Aptamers are powerful candidates for molecular imaging applications due to a number of
attractive features, including rapid blood clearance and tumor penetration. We carried out …

In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548

…, M Dragic, A Johayem, R Valencia, S Borkowski… - Clinical cancer …, 2013 - AACR
Purpose: A novel [ 68 Ga]-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH
2 peptide (BAY86-7548) having high affinity to bombesin …

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours

…, B Waser, R Cescato, K Graham, S Borkowski… - European journal of …, 2011 - Springer
Purpose Radiolabelled somatostatin-based antagonists show a higher uptake in tumour-bearing
mouse models than agonists of similar or even distinctly higher receptor affinity. Very …

Synthesis, 18F-Labeling, and in Vitro and in Vivo Studies of Bombesin Peptides Modified with Silicon-Based Building Blocks

…, K Graham, T Stellfeld, S Borkowski… - Bioconjugate …, 2008 - ACS Publications
The gastrin-releasing peptide receptor (GRPr) is overexpressed on various human tumors.
The goal of our study was the synthesis of new 18 F-labeled bombesin analogues for the PET …

Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men

…, E Kähkönen, P Luoto, S Borkowski… - Journal of Nuclear …, 2013 - Soc Nuclear Med
This first-in-human study investigated the safety, tolerability, metabolism, pharmacokinetics,
biodistribution, and radiation dosimetry of 68 Ga-bombesin antagonist 68 Ga-DOTA-4-amino-…

Direct One-Step18F-Labeling of Peptides via Nucleophilic Aromatic Substitution

…, T Stellfeld, L Lehmann, S Borkowski… - Bioconjugate …, 2009 - ACS Publications
Methods for the radiolabeling molecules of interest with [ 18 F]-fluoride need to be rapid,
convenient, and efficient. Numerous [ 18 F]-labeled prosthetic groups, eg, N-succinimidyl 4 [ 18 F…

Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin

…, ML Tamma, F Braun, S Borkowski… - Journal of nuclear …, 2013 - Soc Nuclear Med
The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate cancer and is
an attractive target for radionuclide therapy. In addition, inhibition of the protein kinase …

Dosimetry and first clinical evaluation of the new 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer

…, L Dinkelborg, K Graham, S Borkowski… - Journal of Nuclear …, 2015 - Soc Nuclear Med
The aim of this first-in-man study was to demonstrate the feasibility, safety, and tolerability,
as well as provide dosimetric data and evaluate the imaging properties, of the bombesin …

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate

D Berndorff, S Borkowski, S Sieger, A Rother… - Clinical cancer …, 2005 - AACR
Purpose: The expression of extra domain B (ED-B) fibronectin is always associated with
angiogenic processes and can be exclusively observed in tissues undergoing growth and/or …